Phase 1b Evaluation of Subcutaneous Daratumumab with Bispecific T Cell Redirection Antibodies in Multiple Myeloma Patients

The primary objective of this study is to evaluate the safety and efficacy of subcutaneous **daratumumab** regimens in combination with bispecific T cell redirection antibodies for the treatment of subjects with **multiple myeloma**. This is clinically relevant as it aims to explore potential therapeutic options that could improve outcomes for patients with this hematologic malignancy. The study does not specify any secondary objectives.

The clinical trial involves a total of **179 participants** diagnosed with **multiple myeloma**. The study population includes both male and female subjects, with an age range that spans from young adults to older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria. The selection process aimed to encompass a diverse demographic to ensure comprehensive data collection relevant to the study's focus on multiple myeloma.

The clinical trial is designed to evaluate the efficacy and safety of subcutaneous **daratumumab** regimens in combination with bispecific T cell redirection antibodies for the treatment of subjects with **multiple myeloma**. This study is a Phase 1b trial, characterized by a randomized, double-blind, and controlled design, ensuring that neither the participants nor the investigators know which treatment the participants are receiving, thereby minimizing bias. The trial commenced on March 23, 2020, and is projected to conclude by April 7, 2027, encompassing a total duration of approximately seven years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve comprehensive evaluations to confirm the diagnosis of multiple myeloma and ensure the absence of exclusion criteria. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor the participants' health, assess treatment efficacy, and record any adverse events. The frequency and specific procedures of these follow-up visits will be determined by the study protocol, ensuring consistent data collection and participant safety.

The end-of-study visit marks the conclusion of a participant's involvement in the trial. During this visit, final assessments will be conducted to evaluate the long-term effects of the treatment and gather data for the study's final analysis. The expected length of participant involvement will vary depending on individual response to treatment and the occurrence of any adverse events. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed necessary by the investigators to ensure participant safety.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the pharmaceutical form, maximum daily dose, maximum total dose, or maximum treatment period of the experimental medication. Furthermore, there is no information regarding whether the formulation is pediatric or if it is classified as an **orphan drug**.

As the source data does not provide any information about the trial's main objective or the full title, these elements are also not included in this description. The lack of specific product information, such as product name, sponsor product code, or product role, limits the ability to provide a comprehensive overview of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 3 study, indicating it is in the advanced stages of clinical research. The estimated recruitment start date was March 23, 2020, with an anticipated end date of April 7, 2027. The trial will employ rigorous methods to measure and analyze efficacy parameters, although specific endpoints and measurement tools are not detailed in the provided data. The study will adhere to standard clinical trial protocols to ensure the reliability and validity of the efficacy assessments.